TP53 and lung adenocarcinoma: The Cancer Genome Atlas (TCGA) reports somatic TP53 mutations in up to 81% of lung and 72% of head and neck squamous cell carcinomas, at one extreme, with a decreasing frequency of 46% in lung adenocarcinoma, 37% in breast carcinoma and 8% in prostate cancer36–41.